Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10166846 | 0.90 | MAPKAPK5 (0.33) | MAPKAPK5KCNH2OPRD1 | |
| SCHEMBL1685240 | 0.86 | MAPKAPK5 (0.41) | MAPKAPK5KCNH2CDK2 | |
| SCHEMBL10166023 | 0.80 | CSF1R (0.39) | MAPKAPK5 | |
| SCHEMBL10165787 | 0.80 | FYN (0.37) | MAPKAPK5CYP2D6CDK2 | |
| SCHEMBL10166168 | 0.80 | PTK6 (0.38) | MAPKAPK5 | |
| SCHEMBL13922249 | 0.78 | MAPKAPK5 (0.42) | MAPKAPK5 | |
| SCHEMBL10166154 | 0.77 | NAMPT (0.39) | MAPKAPK5 | |
| SCHEMBL10166148 | 0.77 | POLB (0.40) | KCNH2 | |
| SCHEMBL10166838 | 0.77 | FYN (0.45) | — | |
| SCHEMBL10166840 | 0.76 | FYN (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | COL2A1, MMP1, COL1A1 | MAPKAPK5 19/4885KCNH2 1598/4885CYP2D6 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.